BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 15074001)

  • 1. DKK1 in multiple myeloma.
    Lu CM
    N Engl J Med; 2004 Apr; 350(14):1464-6; author reply 1464-6. PubMed ID: 15074001
    [No Abstract]   [Full Text] [Related]  

  • 2. DKK1 in multiple myeloma.
    Hofbauer LC; Neubauer A; Schoppet M
    N Engl J Med; 2004 Apr; 350(14):1464-6; author reply 1464-6. PubMed ID: 15074002
    [No Abstract]   [Full Text] [Related]  

  • 3. Identification and clinical relevance of receptor activator of nuclear factor kappaB ligand expression of myeloma cells.
    Heider U; Zavrski I; Jakob C; Fleissner C; Sezer O
    Cancer Res; 2004 Jan; 64(2):773-4; author reply 774-5. PubMed ID: 14744798
    [No Abstract]   [Full Text] [Related]  

  • 4. Lack of receptor activator of nuclear factor-kB ligand (RANKL) expression and functional production by human multiple myeloma cells.
    Giuliani N; Colla S; Morandi F; Barille-Nion S; Rizzoli V
    Haematologica; 2005 Feb; 90(2):275-8. PubMed ID: 15710592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment?
    Giuliani N; Colla S; Rizzoli V; Barillé-Nion S; Bataille R
    Cancer Res; 2004 Jan; 64(2):772-3; author reply 774-5. PubMed ID: 14744797
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiple myeloma.
    Schneider HG; Sentry J
    N Engl J Med; 2005 Feb; 352(8):840-1; author reply 840-1. PubMed ID: 15736296
    [No Abstract]   [Full Text] [Related]  

  • 7. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
    Giuliani N; Colla S; Morandi F; Rizzoli V
    Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of understanding of genetics of Paget's disease of bone and related diseases.
    Takata S; Yasui N; Nakatsuka K; Ralston SH
    J Bone Miner Metab; 2004; 22(6):519-23. PubMed ID: 15490260
    [No Abstract]   [Full Text] [Related]  

  • 9. Sp1 and Sp3 regulate the basal transcription of receptor activator of nuclear factor kappa B ligand gene in osteoblasts and bone marrow stromal cells.
    Liu J; Yang H; Liu W; Cao X; Feng X
    J Cell Biochem; 2005 Nov; 96(4):716-27. PubMed ID: 16052479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DKK1 in multiple myeloma.
    Meyer MA
    N Engl J Med; 2004 Apr; 350(14):1464-6; author reply 1464-6. PubMed ID: 15070800
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells.
    Secchiero P; Corallini F; Barbarotto E; Melloni E; di Iasio MG; Tiribelli M; Zauli G
    J Cell Physiol; 2006 Apr; 207(1):158-64. PubMed ID: 16270354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluid flow induces Rankl expression in primary murine calvarial osteoblasts.
    Mehrotra M; Saegusa M; Wadhwa S; Voznesensky O; Peterson D; Pilbeam C
    J Cell Biochem; 2006 Aug; 98(5):1271-83. PubMed ID: 16514640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone lesions in molecular subtypes of multiple myeloma.
    Robbiani DF; Chesi M; Bergsagel PL
    N Engl J Med; 2004 Jul; 351(2):197-8. PubMed ID: 15247367
    [No Abstract]   [Full Text] [Related]  

  • 14. Implant wear induces inflammation, but not osteoclastic bone resorption, in RANK(-/-) mice.
    Ren W; Wu B; Peng X; Hua J; Hao HN; Wooley PH
    J Orthop Res; 2006 Aug; 24(8):1575-86. PubMed ID: 16779834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2.
    Nadiminty N; Lou W; Lee SO; Mehraein-Ghomi F; Kirk JS; Conroy JM; Zhang H; Gao AC
    Clin Cancer Res; 2006 Mar; 12(5):1420-30. PubMed ID: 16533764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
    Tian E; Zhan F; Walker R; Rasmussen E; Ma Y; Barlogie B; Shaughnessy JD
    N Engl J Med; 2003 Dec; 349(26):2483-94. PubMed ID: 14695408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating rapid responses to 1,25-dihydroxyvitamin D3 with transcriptional changes in osteoblasts: Ca2+ regulated pathways to the nucleus.
    Farach-Carson MC; Bergh JJ; Xu Y
    Steroids; 2004 Aug; 69(8-9):543-7. PubMed ID: 15288767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the pathogenesis of osteolysis in multiple myeloma patients.
    Giuliani N; Colla S; Rizzoli V
    Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrovirus-mediated gene transfer of receptor activator of nuclear factor-kappaB-Fc prevents bone loss in ovariectomized mice.
    Kim D; Cho SW; Her SJ; Yang JY; Kim SW; Kim SY; Shin CS
    Stem Cells; 2006 Jul; 24(7):1798-805. PubMed ID: 16556708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
    Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
    Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.